ALPMY — Astellas Pharma, Inc.
Is ALPMY overbought or oversold? Here is the current MarketMoodz read.
Astellas Pharma, Inc. (ALPMY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $16.90. The rating moved from Overbought to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$16.90
- Last changeMoved from Overbought to Neutral on November 17, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
AI analysis
Astellas Pharma is a large, diversified biopharma with stable cash flows from established specialty franchises and a pipeline that can generate upside through clinical readouts or strategic M&A. Current market dynamics favor defensive large‑cap pharma exposures, which supports relative stability in the near term. Key positives include recurring revenue, access to specialty distribution channels, and balance sheet flexibility. Primary concerns are clinical/regulatory outcomes, pricing and reimbursement pressure, patent expiry risk, and FX exposure. Near‑term price movement is expected to be modest absent major news; catalysts that could move the shares materially include favorable trial data, accretive deals, or changes in payer policy impacting product economics.
Key factors
- Diversified product portfolio with recurring revenue from established oncology, urology and specialty medicines providing cash flow stability
- Large-cap pharma defensive flows in the market support relative valuation stability during risk-off periods
- Pipeline and mid‑late stage programs that can drive upside on positive clinical readouts or label expansions
- M&A and partnership optionality given industry consolidation trends among large pharma seeking specialty franchises
- Operational exposure to specialty distribution and infusion channels benefits from secular shift toward specialty care
- Reasonable balance sheet and free cash generation relative to peer large‑cap pharma (supports R&D and inorganic activity)
- Limited near-term macro shocks in markets and muted geopolitical headlines reducing short-term volatility
Risks
- Clinical or regulatory setbacks on key pipeline programs which would materially reduce forward revenue visibility
- Pricing and reimbursement pressure, including tighter payor scrutiny and potential clawbacks in Medicare/advantaged programs
- Patent expirations and generic competition for established products
- Currency/FX volatility given material operations and revenues in Japan and global markets
- Execution risk on business development or integration following any acquisitions
- Sector competition from rapid growth areas (e.g., obesity/GLP‑1 combos) which could reallocate payer and prescriber priorities
- Adverse macro/market moves that trigger broader de‑risking of cyclical or specialty exposures
See today's live rating, score and targets
Members see the live hourly rating for ALPMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.